メタボリックシンドロームの概念と慢性腎臓病との関連

抄録

Metabolic syndrome (MetS) is a complex disorder combining hypertension, obesity, dyslipidemia, and insulin resistance accompanying abnormal adipose deposition and function. MetS is associated with the development of atherosclerotic cardiovascular disease, and contributes to the development of chronic kidney disease (CKD). A close relationship between MetS and increased risk of developing renal damage has been established. Early diagnosis and treatment of MetS is essential in the forming of strategies to prevent CKD as a result of MetS. Several findings have indicated that the activation of the intrarenal renin-angiotensin system (RAS) may play an important role in the progression of MetS to CKD. Therefore, RAS blockade is a first-line therapeutic target for preventing progression of MetS to CKD. The aim of this article is to provide an overview of the concept of MetS, and to discuss the management of CKD in patients with MetS.